"immune system" = -li- or -lim-2. Syllable before "mab":
chimeric: -xi_
humanized -zu-
fully human -u-
murine -mo-
chimeric human/mouse antibodies are ximabs,
humanized antibodies are zumabs,
fully human antibodies are umabs,
murines are momabs.
| Chemical or Common Name | Brand Name | Other Names | Molecular Target | Molecular Structure | Licensed Indication, Major Target Diseases | Manufacturer and/or Distributor |
| Abciximab | ReoPro | c7E3 Fab | Glycoprotein (GP) IIb/IIIa receptor of human platelets | chimeric/human monoclonal antibody; Fab portion | cardiac ischemia | Centocor Eli Lilly |
| Adalimumab | Humira | Trudexa | TNFα (Tumor Necrosis Factor-alpha) | human IgG1κ, recombinant | rheumatoid arthritis; juvenile idiopathic arthritis; psoriatic arthritis; ankylosing spondylitis; Crohn's disease; plaque psoriasis | Abbott |
| Alemtuzumab | Campath | Campath-1H, Mabcampath | CD52 (cell surface glycoprotein) | humanized IgG1κ, recombinant | Chronic B-lymphocyte Leukemia (B-CLL) | Genzyme Bayer Healthcare Pharmaceuticals |
| Basiliximab | Simulect | CD25 (IL-2Rα) | chimeric IgG1κ, recombinant | prophylaxis of acute organ rejection in adults following cadaveric- or living-donor renal transplantation | Novartis | |
| Bevacizumab | Avastin | rhuMAb VEGF | VEGF (Vascular Endothelial Growth Factor) | humanized monoclonal antibody | metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-small cell lung cancer | Genentech |
| Certolizumab pegol | Cimzia | TNFα | humanized, recombinant Fab' fragment conjugated to polyethylene glycol | Crohn's disease | UCB Pharma Nektar (XOMA) | |
| Cetuximab | Erbitux | EGF (Epidermal Growth Factor) receptor | chimeric monoclonal antibody | metastatic colorectal cancer, head and neck cancer | Imclone & Bristol-Meyers Squibb (North America); Merck KGaA (other areas) | |
| Daclizumab | Zenapax | CD25 (IL-2Rα) | humanized IgG1 monoclonal antibody | renal allograft rejection | PDL Roche | |
| Eculizumab | Soliris | 5G1.1 | complement protein C5 | humanized | Paroxysmal nocturnal hemoglobinuria | Alexion Pharmaceuticals |
| Chemical or Common Name | Brand Name | Other Names | Molecular Target | Molecular Structure | Licensed Indication, Major Target Diseases | Manufacturer and/or Distributor |
| Efalizumab | Raptiva | Xanelin, hu 1124 | CD11a (α-subunit of leukocyte function antigen-1 [LFA-1]) | humanized IgG1κ, recombinant | chronic, moderate to severe plaque psoriasis | Genentech (XOMA) |
| Gemtuzumab ozogamicin | Mylotarg | hP67.6 | CD33 | Humanized IgG4κ, conjugated with the toxin calicheamicin | CD33 positive Acute Myeloid Leukemia | Wyeth |
| Ibritumomab tiuxetan | Zevalin | CD20 | murine IgG1κ monoclonal antibody, conjugated to a chelator (tiuxetan) for labeling with Indium-111 or Yttrium-90 | non-Hodgkins Lymphoma (CD20 positive, low-grade or follicular) which is relapsed or refractory to rituximab, in combination with rituximab | Cell Therapeutics Biogen Idec | |
| Infliximab | Remicade | TNF | chimeric IgG1κ, recombinant | rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; chronic severe plaque psoriasis; crohn's disease; ulcerative colitis | Centocor JOM | |
| Muromonab-CD3 | Orthoclone OKT3 | CD3 | murine IgG2a | renal, cardiac, hepatic allograft rejection | Ortho Biotech | |
| Natalizumab | Tysabri | α4-subunit of α4-β1 and α4-β7 integrins; blocks binding of VLA4 to VCAM-1 and binding of α4-β7 to MADCAM-1 | humanized IgG4κ | Relapsing forms of MS, Crohn's Disease | Elan Pharmaceuticals & Biogen Idec | |
| Omalizumab | Xolair | IgE | humanized IgG1κ, recombinant | moderate to severe IgE-mediated, persistent asthma (US) or severe asthma (EU), in adults and children over 12 years old, inadequately controlled by inhaled corticosteroid treatment | Genentech & Novartis | |
| Chemical or Common Name | Brand Name | Other Names | Molecular Target | Molecular Structure | Licensed Indication, Major Target Diseases | Manufacturer and/or Distributor |
| Palivizumab | Synagis | MEDI-493 | RSV F (fusion) protein | humanized IgG1κ | prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease | Medimmune |
| Panitumumab | Vectibix | ABX-EGF | human EGFR (Epidermal Growth Factor Receptor) | recombinant human IgG2κ monoclonal antibody | treatment of EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens | Amgen |
| Ranibizumab | Lucentis | rhuFab V2; IgG1k (derived from Avastin (bevacizumab) | VEGF-A | humanized IgG1κ Fab fragment | neovascular (wet) age-related macular degeneration | Genentech (XOMA) |
| Rituximab | Rituxan | Mabthera | CD20 | chimeric IgG1κ, recombinant | rheumatoid arthritis; B-cell non-Hodgkin's lymphoma | Genentech |
| Tocilizumab | Actemra | MRA | IL-6 receptor (IL-6R) | humanized, recombinant | Rheumatoid Arthritis (Japan), systemic-onset Juvenile Idiopathic Arthritis (Japan) | F.Hoffman-La Roche and Chugai Pharmaceuticals |
| Tositumomab I131 | Bexxar | CD20 | murine, monoclonal; covalently bound to Iodine-131 | non-Hodgkins Lymphoma (CD20 positive, follicular) which is refractory to rituximab and relapsed following chemotherapy | GlaxoSmithKline | |
| Trastuzumab | Herceptin | c-erbB2/HER2 | humanized receptor antagonist | HER2 overexpressing breast cancer | Genentech | |
| Chemical or Common Name | Brand Name | Other Names | Molecular Target | Molecular Structure | Licensed Indication, Major Target Diseases | Manufacturer and/or Distributor |
NO RELIANCE FOR MEDICAL DECISIONSInformation, services and/or other features contained in this web site (including any electronic bulletin board contained therein) are being provided for general educational and informational purposes only and are not intended to be a substitute for independent medical judgment or constitute case-specific medical advice or treatment in any way. Such information, services and/or features are not intended to serve as the primary basis for making personal or professional medical decisions, nor are they intended to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to making any treatment or diagnosis decisions and with any questions you may have regarding a medical condition or its diagnosis or treatment. You should confirm any information obtained from this site with other sources before undertaking any treatment or otherwise taking any actions relating thereto. Any reliance on any information, services or other features contained in this site is solely at your own risk. |
|
Clinical Immunology Society 555 East Wells Street, Suite 1100 Milwaukee, WI 53202-3823 USA Phone: 414/224-8095 | Fax: 414/272-6070 Email: info@clinimmsoc.org © 2001-2008 Clinical Immunology Society | Web Site Disclaimer |
